

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 18931

Title: Personalized medicine in gastric cancer: Where are we and where are we going?

Reviewer's code: 03016888

Reviewer's country: Japan

Science editor: Jing Yu

Date sent for review: 2015-05-07 07:36

Date reviewed: 2015-07-23 12:00

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input checked="" type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
	<input type="checkbox"/> Grade D: Rejected	BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

This manuscript is comprehensively reviewing chemotherapy and anti-targeting therapy associated with TCGA subgroups for advanced gastric cancer. Besides, clinical trials which are now on-going and recently have been reported are described. This paper can be well-written and understandable for readers. 1. In page 9 line 6-9, the authors mentioned about the comparison between Western and Eastern patients. The authors should add the references showing the data of Eastern patients. 2. In page 9, the authors mentioned "driver mutations". In gastric cancer, driver mutation has not been identified although RTK/RAS (such as HER2, EGFR, FGFR, MET) has been recognized. The authors should make sure the definition of the term "driver mutation". 3. As for the clinical trial with T-DM1, this trial compares T-DM1 with taxane (not only paclitaxel but also docetaxel) as the 2nd line chemotherapy. The authors should revise. 4. In page 13 line 17-20, the authors compared the data between REGARD and RAINBOW trials. But, this historical comparison is unacceptable, because some percentages of patients participated in RAINBOW received 3rd line therapy whereas a few percentages of patients received subsequent chemotherapy in REGARD. There are lots of different points between the patients in REGARD and RAINBOW. It is impossible to compare both trials, and

that will mislead readers. 5. In page 16, the authors mentioned a randomized phase II study with AZD4547 (SHINE study). The result of this study was already reported in ASCO 2015 (abstr 4014). This study was negative. The authors had better to update. 6. In MET paragraph, the clinical trials with onartuzumab was reported in ASCO 2015 (abstr 4012). Moreover, RILOMET-1 and MEGA study were also negative in ASCO 2015 (abstr 4000 and 4013). 7. The authors reviewed according to targeted molecule. However, there are active phase III studies which are mentioned in this manuscript. One is a olaparib which is a PARP inhibitor (NCT01924533), and another is BBI-608 which targets STAT3 (NCT02178956). The adding the information about these agents and clinical trials will help this paper to be more comprehensive and highly complete. 8. In the last page of this manuscript, Table 1 is listed. However, there is no term "Table 1" in the text. The authors should insert the term "Table 1" in the appropriate position.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 18931

Title: Personalized medicine in gastric cancer: Where are we and where are we going?

Reviewer's code: 03017210

Reviewer's country: Taiwan

Science editor: Jing Yu

Date sent for review: 2015-05-07 07:36

Date reviewed: 2015-07-20 12:00

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		<input checked="" type="checkbox"/> No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

Cancer treatment has stepped into a significant milestone in the advancement of understanding of human diseases and its management, based on sequenced genes from human genome. The well-established personalized cancer treatment is breast cancer. In gastric cancer, the first molecular target that has been studied extensively in gastric cancer is Her-2. Currently, gastric cancer is classified into four molecular classification, including EBV, MSI, GS, and CIN type. The authors reviewed the established signaling pathway and compare the correlation between the four molecular subtype. Authors also reviewed current clinical trial of targeted therapy in gastric cancer. Gastric cancer may stepped into personalized treatment in the future.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 18931

Title: Personalized medicine in gastric cancer: Where are we and where are we going?

Reviewer's code: 00253956

Reviewer's country: United Kingdom

Science editor: Jing Yu

Date sent for review: 2015-05-07 07:36

Date reviewed: 2015-07-20 16:04

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input checked="" type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Duplicate publication	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> Plagiarism	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E: Poor		[Y] No	<input type="checkbox"/> Major revision
		BPG Search:	
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		[Y] No	

COMMENTS TO AUTHORS

The manuscript by Jacome et al 2015 "personalised medicine in gastric cancer: where are we and where are we going"? provides an insight into the molecular basis of gastric cancer, and also up to date data from clinical trials that attempts to evaluate the usefulness of current drug therapies, and a rationale for their effectiveness. The manuscript is well written and informative, and should provide a useful reference text for researchers in this field. I therefore have no reservations about publication of the manuscript without revision.

ESPS PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

ESPS manuscript NO: 18931

Title: Personalized medicine in gastric cancer: Where are we and where are we going?

Reviewer's code: 00001832

Reviewer's country: Germany

Science editor: Jing Yu

Date sent for review: 2015-05-07 07:36

Date reviewed: 2015-07-13 23:57

CLASSIFICATION	LANGUAGE EVALUATION	SCIENTIFIC MISCONDUCT	CONCLUSION
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language polishing	<input type="checkbox"/> The same title	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C: Good		<input type="checkbox"/> Duplicate publication	
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of language polishing	<input type="checkbox"/> Plagiarism	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E: Poor	<input type="checkbox"/> Grade D: Rejected	<input checked="" type="checkbox"/> No	<input checked="" type="checkbox"/> Minor revision
		BPG Search:	<input type="checkbox"/> Major revision
		<input type="checkbox"/> The same title	
		<input type="checkbox"/> Duplicate publication	
		<input type="checkbox"/> Plagiarism	
		<input checked="" type="checkbox"/> No	

COMMENTS TO AUTHORS

The manuscript by Jacome and coworkers reviews personalized medicine in gastric cancer with special emphasis on its genomic landscape. This is an interesting and comprehensive review regarding this topic. However, the authors could consider a few comments/suggestions. ? The standard treatment of localized or resectable locally advanced GC depends on the country/region. The authors could comment on the different approaches, i.e. adjuvant chemotherapy, perioperative therapy, adjuvant radio-chemotherapy. ? The authors might include information in table 1, whether the trial was positive or negative. ? Figures 1&2: in the heading it is stated 'driver mutations'; however, HER2 (as an example) is not mutated but overexpressed or amplified. Similarly, I am not sure whether alterations in immune checkpoints can be called 'driver' mutations/alterations. ? There are few grammatical and typographical errors e.g. highlighting that should be corrected.